JP2007537289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537289A5 JP2007537289A5 JP2007513391A JP2007513391A JP2007537289A5 JP 2007537289 A5 JP2007537289 A5 JP 2007537289A5 JP 2007513391 A JP2007513391 A JP 2007513391A JP 2007513391 A JP2007513391 A JP 2007513391A JP 2007537289 A5 JP2007537289 A5 JP 2007537289A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- disease
- substituted
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims description 13
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 206010003246 Arthritis Diseases 0.000 claims description 4
- 206010007554 Cardiac failure Diseases 0.000 claims description 4
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010011401 Crohn's disease Diseases 0.000 claims description 4
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 4
- 208000009745 Eye Disease Diseases 0.000 claims description 4
- 206010019280 Heart failure Diseases 0.000 claims description 4
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 4
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010038683 Respiratory disease Diseases 0.000 claims description 4
- 208000006641 Skin Disease Diseases 0.000 claims description 4
- 201000001320 atherosclerosis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000006704 ulcerative colitis Diseases 0.000 claims description 4
- 201000011528 vascular disease Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 230000036523 atherogenesis Effects 0.000 claims description 2
- 230000000051 modifying Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- -1 hydrate Substances 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000003205 Muscles Anatomy 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000005418 aryl aryl group Chemical group 0.000 claims 3
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 3
- 230000003247 decreasing Effects 0.000 claims 3
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000010874 syndrome Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022489 Insulin resistance Diseases 0.000 claims 2
- 108010015181 PPAR delta Proteins 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 235000020828 fasting Nutrition 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 230000002641 glycemic Effects 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000001771 impaired Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006410 propenylene group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010061428 Decreased appetite Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000003577 HIV Wasting Syndrome Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101700006801 THBI Proteins 0.000 claims 1
- 229960003604 Testosterone Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 235000021407 appetite control Nutrition 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptors Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- CAOUTCDDAKSUJP-UHFFFAOYSA-N methyl 2-(4-acetyl-2-methylphenoxy)acetate Chemical compound COC(=O)COC1=CC=C(C(C)=O)C=C1C CAOUTCDDAKSUJP-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57100404P | 2004-05-14 | 2004-05-14 | |
| PCT/US2005/016747 WO2005113506A1 (en) | 2004-05-14 | 2005-05-13 | Compounds and compositions as ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537289A JP2007537289A (ja) | 2007-12-20 |
| JP2007537289A5 true JP2007537289A5 (pt) | 2008-02-07 |
Family
ID=35428365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513391A Pending JP2007537289A (ja) | 2004-05-14 | 2005-05-13 | Ｐｐａｒモジュレーターとしての化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7745445B2 (pt) |
| EP (1) | EP1756062A4 (pt) |
| JP (1) | JP2007537289A (pt) |
| KR (1) | KR20070026503A (pt) |
| CN (1) | CN1980894A (pt) |
| AU (1) | AU2005245418B2 (pt) |
| BR (1) | BRPI0510024A (pt) |
| CA (1) | CA2564365A1 (pt) |
| MX (1) | MXPA06013195A (pt) |
| RU (1) | RU2006144121A (pt) |
| WO (1) | WO2005113506A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
| ES2449618T3 (es) | 2005-06-30 | 2014-03-20 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-delta |
| JP2009513633A (ja) * | 2005-10-25 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | 糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−４インヒビターと降圧薬との組合せ |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| EP1993531B1 (en) * | 2006-03-02 | 2015-10-14 | Warner Chilcott Company, LLC | Extended cycle multiphasic oral contraceptive method |
| CA2645719A1 (en) * | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| AU2007341981A1 (en) * | 2006-12-29 | 2008-07-10 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
| US8080658B2 (en) * | 2007-07-10 | 2011-12-20 | Idemitsu Kosan Co., Ltd. | Material for organic electroluminescent element and organic electroluminescent element employing the same |
| WO2009012650A1 (fr) * | 2007-07-25 | 2009-01-29 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Dérivés d'arylpyrimidine, procédés de préparation et utilisations pharmaceutiques de ces dérivés |
| CA2708391A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
| EP2299823A1 (en) * | 2008-05-19 | 2011-03-30 | The University of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| EP2424509A4 (en) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | MEDICINAL COMBINATION FORMULATIONS WITH DETERMINED DOSAGE |
| JP6223680B2 (ja) | 2010-02-09 | 2017-11-01 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ヒドラジンで置換されているアントラニル酸誘導体 |
| EP2582691B1 (de) | 2010-06-15 | 2017-05-10 | Bayer Intellectual Property GmbH | Anthranilsäurederivate |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| TWI683808B (zh) * | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH08333287A (ja) * | 1995-06-02 | 1996-12-17 | Fuji Yakuhin Kogyo Kk | 芳香環置換アルキルカルボン酸及びアルカノール誘導体とそれらを含有する抗血栓剤 |
| US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
| IL150260A0 (en) * | 2000-01-28 | 2002-12-01 | Novo Nordisk As | Propionic acid derivatives and their use in the treatment of diabetes and obesity |
| WO2002076438A2 (en) * | 2001-03-23 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| DE60333211D1 (de) * | 2002-10-28 | 2010-08-12 | High Point Pharmaceuticals Llc | Neue verbindungen und deren verwendung als ppar-modulatoren |
| ES2352085T3 (es) * | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
-
2005
- 2005-05-13 JP JP2007513391A patent/JP2007537289A/ja active Pending
- 2005-05-13 EP EP05751010A patent/EP1756062A4/en not_active Withdrawn
- 2005-05-13 CN CNA2005800196459A patent/CN1980894A/zh active Pending
- 2005-05-13 KR KR1020067023755A patent/KR20070026503A/ko not_active Application Discontinuation
- 2005-05-13 AU AU2005245418A patent/AU2005245418B2/en not_active Ceased
- 2005-05-13 RU RU2006144121/04A patent/RU2006144121A/ru not_active Application Discontinuation
- 2005-05-13 BR BRPI0510024-0A patent/BRPI0510024A/pt not_active IP Right Cessation
- 2005-05-13 MX MXPA06013195A patent/MXPA06013195A/es not_active Application Discontinuation
- 2005-05-13 CA CA002564365A patent/CA2564365A1/en not_active Abandoned
- 2005-05-13 US US11/596,598 patent/US7745445B2/en not_active Expired - Fee Related
- 2005-05-13 WO PCT/US2005/016747 patent/WO2005113506A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537289A5 (pt) | ||
| JP7057317B2 (ja) | 疾患の治療のための二重機構阻害剤 | |
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| JP2008513516A5 (pt) | ||
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| JP5043105B2 (ja) | 有機化合物 | |
| TWI691475B (zh) | Ｕｒａｔ１抑制劑 | |
| US9737522B2 (en) | NMDA receptor modulators and uses related thereto | |
| TW200848026A (en) | Dihydroindazole compounds useful in treating iron disorders | |
| RU2746602C2 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| JP2008513499A5 (pt) | ||
| WO2007097403A1 (ja) | 消化管潰瘍治療又は予防薬 | |
| AU6582300A (en) | Benzoic acid derivatives for the treatment of diabetes mellitus | |
| JP2016500063A5 (pt) | ||
| TW200843733A (en) | Biaryl and biheteroaryl compounds useful in treating iron disorders | |
| JP2007531764A5 (pt) | ||
| JP5946192B2 (ja) | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬 | |
| JP2010522710A5 (pt) | ||
| AU2015336458A1 (en) | KCNQ2-5 channel activator | |
| JP2017008091A (ja) | 癌の治療のための化合物 | |
| WO2014017093A1 (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| RU2001120723A (ru) | Производные имидазола и их медицинское применение | |
| JP2007522178A5 (pt) | ||
| KR102425709B1 (ko) | Dp 길항제 |